RIGI and neoplasm: Based on the role of NA sensing in antitumor immunity, cGAS-STING and RIG-I/MDA5 agonists have been developed for cancer immunotherapy, even though some controversial studies have also shown that inappropriate activation of STING and RIG-I signaling can contribute to a suppressive TME and promote tumor growth and metastasis [102].